
## **Condensed Interim**

# Un-Audited Financial Statements For the 1st Quarter Ended

## 30th September 2023





### **COMPANY'S INFORMATION**

| Board of Director        | Mian Shahzad Aslam<br>Mian Farrukh Naseem<br>Mian Aamir Naseem<br>Mr. Maqbool Hussain Bhutta<br>Mr. Asim Mehmood Bhatti<br>Mr. Muhammad Abbas<br>Mr. Muhammad Irfan | CEO / Director<br>Director<br>Director<br>Director<br>Director<br>Director<br>Director |  |  |  |  |  |
|--------------------------|---|--|--|--|--|--|--|
| Audit Committee:         | Mr. Muhammad Irfan  | Chairman   |  |  |  |  |  |
|                          | Mr. Muhammad Abbas  | Member   |  |  |  |  |  |
|                          | Mr. Asim Mehmood Bhatti   | Member   |  |  |  |  |  |
| HR & R Committee:        | Mr. Asim Mehmood Bhatti   | Chairman   |  |  |  |  |  |
|                          | Mr. Muhammad Irfan  | Member   |  |  |  |  |  |
|                          | Mr. Muhammad Abbas  | Member   |  |  |  |  |  |
| Chief Financial Officer: | Mr. Maqbool Hussain Bhutta  |  |  |  |  |  |  |
| Company Secretary:       | Mr. Ahsan Raza  |  |  |  |  |  |  |
| Auditors:                | Kamran & Co.<br>Chartered Accountants<br>Apartment # A/2, Ingola Apartments<br>24 Jail Road, Lahore.  |  |  |  |  |  |  |
| Bankers:                 | National Bank Of Pakistan<br>Habib Bank Limited<br>Muslim Commercial Bank Ltd.  |  |  |  |  |  |  |
| Share Registrar          | Corplink (Pvt) Ltd.<br>1-K Commercial Modal Town, Lahore.<br>Tel: 042-3561714, 35839182, 35916719   |  |  |  |  |  |  |
| Registered Office:       | 61-K, Gulberg III, Lahore.<br>Ph: 042-35763736 Fax: 042-3   | 5763768  |  |  |  |  |  |
| Mill:                    | 8-Km, Faisalabad Road,Aslamabad,<br>Khaareyanwala, Sheikhupura.<br>Ph: 056-3544053  |  |  |  |  |  |  |

### DIRECTORS' REPORT TO THE SHAREHOLDERS

The Results for quarter under review show a loss after tax amounting to rupees 2.954 Million after accounting for administrative expenses of Rs. 3.776 Million including depreciation of Rs. 3.084 million and other operating expenses were Rs. Nil and financial cost was also Nil.

During the quarter period ended September 30, 2023, the operation of the mills remained Closed. The company has started the business of dairy. During the period under consideration, sales proceed was rupees 6.336 Million. The management is trying to extend the dairy business.

The Management is also trying to secure electric connection to resume its main line of business i.e. spinning.

The management is doing its best efforts to settle all the cases with Banks and is doing negotiation with banks and making all efforts to review the operation of mills.

Moreover, the management had decided to change the main line of business from Textile to Dairy and Real Estate. In this regard a business has been initiated.

The Management is also trying to obtain electricity connection to restart the production process of the mill.

The Management of the Company is hopeful that the operation of the Mill will be re-started in near future.

For and on behalf of the Board of Directors

Chief Executive Officer

5nA

Lahore October 26, 2023

### CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION

AS AT 30 SEPTEMBER 2023

|  |          | UN-AUDITED    | D AUDITED    |  |
|--|----------|---------------|--------------|--|
|  |          | Sep 30, 2023  | 30 Jun, 2023 |  |
|  |          | Book Value    | Book Value   |  |
|  | Notes    | Rupees        | Rupees       |  |
| ASSETS   |          |               |              |  |
| NON CURRENT ASSESTS  | _        |               |              |  |
|  |          |               |              |  |
| Property, Plant & Equipment  | 5        | 358,892,933   | 361,977,354  |  |
| Capital Work In Progress   |          | 3,019,890     | 3,019,890    |  |
| Biological Assets  |          | 5,282,560     | 3,302,307    |  |
| Investments  |          | 3,838,000     | 3,838,000    |  |
|  |          | 371,033,383   | 372,137,551  |  |
| CURRENT ASSETS   |          |               |              |  |
| Stores & Spares  | _        | 1,534,873     | 1,534,873    |  |
| Trade Debts  |          | 1,066,924     | 1,016,924    |  |
| Advances, Prepayments & Other Receivables                                      | 6        | 12,644,817    | 12,736,571   |  |
| Cash & Bank Balances   | -        | 6,836,538     | 8,644,771    |  |
|  |          | 22,083,152    | 23,933,139   |  |
| TOTAL ASSETS   |          | 393,116,535   | 396,070,690  |  |
| EQUITY AND LIABLITIES  |          |               |              |  |
|  |          |               |              |  |
| Authorized Capital:<br>25,000,000 (2016 : 25,000,000) ordinary shares of Rs. 1 | 0/- each | 250,000,000   | 250,000,000  |  |
| Issued, Subscribed & Paid Up Capital   |          | 230,000,000   | 230,000,000  |  |
| Capital Reserve  |          | 434,000       | 434,000      |  |
| Deficiet on Remeasurement of Available For Sale Invest                         | tments   | (479,125)     | (479,125     |  |
| Revenue Reserve - General  |          | 45,829,500    | 45,829,500   |  |
| Surplus on Revaluation of Operating Fixed Assets                               |          | 306,683,595   | 306,683,595  |  |
| Accumulated Loss   | _        | (410,021,693) | (407,067,537 |  |
|  | _        | 172,446,277   | 175,400,433  |  |
| NON CURRENT LIABLITIES   | _        |               |              |  |
| Long Term Loansg   |          | 10.500.051    | 10 500 051   |  |
| Deffered Tax Liabilities   |          | 12,588,971    | 12,588,971   |  |
| CURRENT LIABILITIES  |          |               |              |  |
| Short Term Financing   |          | 206,896,985   | 206,896,985  |  |
| Trade and Other Payables   |          | 1,004,764     | 1,004,764    |  |
| Provision For Taxation - Net   |          | 179,537       | 179,537      |  |
|  |          | 208,081,286   | 208,081,286  |  |
| CONTINGENCIES & COMMITMENTS  |          | -             | -            |  |
|  |          |               |              |  |
|  |          |               | -            |  |
|  |          |               |              |  |

### PROFIT AND LOSS ACCOUNT

### FOR THE 1ST QUARTER ENDED SEPTMBER 30, 2023

### (UN AUDITED)

|      | (UN A                            | UDITED) |               |               |
|------|----------------------------------|---------|---------------|---------------|
|      |                                  |         | UN-AUDITED    | UN-AUDITED    |
|      |                                  |         | September 30, | September 30, |
|      |                                  | Note    | 2023          | 2022          |
|      |                                  |         | Rupees        | Rupees        |
| Sale | s - net                          |         | 6,336,490     | 2,191,490     |
| Cos  | t of sales                       |         | (5,520,144)   | (2,475,445    |
| GR   | DSS PROFIT/(LOSS)                |         | 816,346       | (283,955)     |
| Ope  | rating expenses:                 |         |               |               |
| 1    | Administrative                   |         | (3,776,410)   | (5,114,839)   |
|      | Selling and distribution         |         |               | -             |
| OPI  | ERATING PROFIT / (LOSS)          |         | (2,960,064)   | (5,398,794    |
|      | incial charges                   |         | (696)         | -             |
| Oth  | er income                        |         | 6,604         | 252,039       |
| PRO  | DFIT / (LOSS) BEFORE TAXATION    |         | (2,954,156)   | (5,146,755    |
| Taxa | ation                            |         | -             | -             |
| PRO  | DFIT / (LOSS) AFTER TAXATION AND |         | (2,954,156)   | (5,146,755    |
| Acc  | umulated Loss Brought forward    |         | (407,067,537) | (391,716,397  |
|      |                                  |         | (410,021,693) | (396,863,152  |
|      | RNING PER SHARE                  |         | (0.13)        | (0.22)        |

| Cheif Executive | <b>Chief Financial officer</b> | Director |  |
|-----------------|--------------------------------|----------|--|
|                 |                                |          |  |

### CASH FLOW STATEMENT FOR THE 1ST QUARTER ENDED SEPTEMBER 30, 2023

| Cash Flow from Operating Activities         Profit / (Loss) before taxation         Adjustment for:         Depreciation         Financial charges         Other Income         Loan Written Off         Operating profit before working capital changes         (Increase)/decrease in current assets         Stores and spares         Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisition Biological Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activiti  | eptember 30,<br>2023 | September 30<br>2022 |
|--|----------------------|----------------------|
| Profit / (Loss) before taxation       Adjustment for:         Depreciation       Financial charges         Other Income       Coan Written Off         Loan Written Off       Coperating profit before working capital changes         (Increase)/decrease in current assets       Stores and spares         Trade debts       Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities       Creditors, accrued and other liabilities         Cash generated from operating activities       Cash from/(used in) operating activities         Payment for the Aqqisition of Biological Assets       Payment for the Aqqisition of Biological Assets         Payment for the Aqqisition Biological Assets       Fixed Assets         Short Term Loan Paid       Cash rom/(used in) investing activities         Fixed Assets       Short Term Loan Paid         Loan From Related parties       Share Deposit Money         Net cash (used in)/from financing activities       Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period       Cash and cash equivalents  | Rupees               | Rupees               |
| Adjustment for:  |                      |                      |
| Depreciation         Financial charges         Other Income         Loan Written Off         Operating profit before working capital changes         (Increase)/decrease in current assets         Stores and spares         Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period  | (2,954,156)          | (5,146,755           |
| Depreciation         Financial charges         Other Income         Loan Written Off         Operating profit before working capital changes         (Increase)/decrease in current assets         Stores and spares         Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period  |                      |                      |
| Financial charges         Other Income         Loan Written Off         Operating profit before working capital changes         (Increase)/decrease in current assets         Stores and spares         Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period   | 3,084,421            | 1,985,733            |
| Loan Written Off<br>Derating profit before working capital changes<br>(Increase)/decrease in current assets<br>Stores and spares<br>Trade debts<br>Advances, deposits, prepayments and other receivables<br>Advances, deposits, prepayments and other receivables<br>Creditors, accrued and other liabilities<br>Creditors, accrued and other liabilities<br>Increase from/(used in) operating activities<br>Cash flow from Financing Activities<br>Share Deposit Money<br>Net cash (used in)/from financing activities<br>Increase in cash and cash equivalents<br>Cash and cash equivalents at the beginning of Period | 696                  | -                    |
| Operating profit before working capital changes         (Increase)/decrease in current assets         Stores and spares         Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period   | (6,604)              | (252,039             |
| (Increase)/decrease in current assets         Stores and spares         Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period  | -                    | -                    |
| (Increase)/decrease in current assets         Stores and spares         Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period  | 3,078,513            | 1,733,694            |
| Stores and spares         Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period   | 124,357              | (3,413,06            |
| Stores and spares         Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period   |                      |                      |
| Trade debts         Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period   | -                    | -                    |
| Advances, deposits, prepayments and other receivables         Increase/(decrease) in current liabilities         Creditors, accrued and other liabilities         Cash generated from operations         Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period   | (50,000)             | -                    |
| Increase/(decrease) in current liabilities<br>Creditors, accrued and other liabilities<br>Cash generated from operations<br>Income tax paid<br>OtherIncome<br>Financial charges paid<br>Net cash from/(used in) operating activities<br>Payment for the Aqqisitionof Biological Assets<br>Payment for the Aqqisitionof Biological Equipments<br>Net cash from/(used in) investing activities<br>Payment for the Aqqisitionof Biological Equipments<br>Net cash from/(used in) investing activities<br>Fixed Assets<br>Short Term Loan Paid<br>Loan From Related parties<br>Share Deposit Money<br>Net cash (used in)/from financing activities<br>Increase in cash and cash equivalents<br>Cash and cash equivalents at the beginning of Period  | 91,754               | (40,000              |
| Creditors, accrued and other liabilities Cash generated from operations Income tax paid OtherIncome Financial charges paid Net cash from/(used in) operating activities Payment for the Aqqisitionof Biological Assets Payment for the Aqqisitionof Biological Equipments Payment for the Aqqisition Biological Equipments Net cash from/(used in) investing activities Fixed Assets Short Term Loan Paid Loan From Related parties Share Deposit Money Net cash (used in)/from financing activities Increase in cash and cash equivalents Cash and cash equivalents at the beginning of Period  | 41,754               | (40,000              |
| Creditors, accrued and other liabilities Cash generated from operations Income tax paid OtherIncome Financial charges paid Net cash from/(used in) operating activities Payment for the Aqqisitionof Biological Assets Payment for the Aqqisitionof Biological Equipments Payment for the Aqqisition Biological Equipments Net cash from/(used in) investing activities Fixed Assets Short Term Loan Paid Loan From Related parties Share Deposit Money Net cash (used in)/from financing activities Increase in cash and cash equivalents Cash and cash equivalents at the beginning of Period  |                      |                      |
| Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisition of Biological Assets         Payment for the Aqqisition of Biological Equipments         Net cash from/(used in) investing activities         Payment for the Aqqisition of Biological Equipments         Shert cash from/(used in) investing activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period  |                      | -                    |
| Income tax paid         OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Payment for the Aqqisition of Biological Assets         Payment for the Aqqisition of Biological Equipments         Net cash from/(used in) investing activities         Payment for the Aqqisition of Biological Equipments         Shert cash from/(used in) investing activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period  | 166,111              | (3,453,06            |
| OtherIncome         Financial charges paid         Net cash from/(used in) operating activities         Cash Flow from Investing Activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Augument for the Aqqisition of Biological Equipments         Payment for the Aqqisition of Biological Equipments         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period   | ,                    |                      |
| Financial charges paid         Net cash from/(used in) operating activities         Cash Flow from Investing Activities         Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Net cash from/(used in) investing activities         Rest cash from/(used in) investing activities         Pixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Cash and cash equivalents  |                      | 1,857                |
| Net cash from/(used in) operating activities       Image: Cash Flow from Investing Activities         Cash Flow from Investing Activities       Image: Cash Flow from Financing Activities         Payment for the Aqqisitionof Biological Assets       Image: Cash from/(used in) investing activities         Net cash from/(used in) investing activities       Image: Cash Flow from Financing Activities         Fixed Assets       Image: Cash Flow from Financing Activities         Short Term Loan Paid       Image: Cash function financing activities         Net cash (used in)/from financing activities       Image: Cash and cash equivalents         Cash and cash equivalents at the beginning of Period       Image: Cash and cash equivalents   | 6,604                | 252,039              |
| Cash Flow from Investing Activities Payment for the Aqqisitionof Biological Assets Payment for the Aqqisitionof Biological Equipments Net cash from/(used in) investing activities Cash Flow from Financing Activities Fixed Assets Short Term Loan Paid Loan From Related parties Share Deposit Money Net cash (used in)/from financing activities Increase in cash and cash equivalents Cash and cash equivalents at the beginning of Period   | (696)                | -                    |
| Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Payment for the Aqqisitionof Biological Equipments         Net cash from/(used in) investing activities         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period  | 172,019              | (3,199,16            |
| Payment for the Aqqisitionof Biological Assets         Payment for the Aqqisitionof Biological Equipments         Payment for the Aqqisitionof Biological Equipments         Net cash from/(used in) investing activities         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period  |                      |                      |
| Payment for the Aqqisition of Biological Equipments         Net cash from/(used in) investing activities         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period   | (1,980,253)          | -                    |
| Net cash from/(used in) investing activities         Cash Flow from Financing Activities         Fixed Assets         Short Term Loan Paid         Loan From Related parties         Share Deposit Money         Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period   | (1,980,233)          | (334,000             |
| Cash Flow from Financing Activities Fixed Assets Short Term Loan Paid Loan From Related parties Share Deposit Money Net cash (used in)/from financing activities Increase in cash and cash equivalents Cash and cash equivalents at the beginning of Period  |                      | (354,000             |
| Fixed Assets Short Term Loan Paid Loan From Related parties Share Deposit Money Net cash (used in)/from financing activities Increase in cash and cash equivalents Cash and cash equivalents at the beginning of Period  | (1,980,253)          | (334,000             |
| Short Term Loan Paid   |                      |                      |
| Short Term Loan Paid   |                      |                      |
| Loan From Related parties       Share Deposit Money         Net cash (used in)/from financing activities   | -                    | _                    |
| Share Deposit Money Net cash (used in)/from financing activities Increase in cash and cash equivalents Cash and cash equivalents at the beginning of Period  | -                    | _                    |
| Net cash (used in)/from financing activities         Increase in cash and cash equivalents         Cash and cash equivalents at the beginning of Period  | -                    | _                    |
| Cash and cash equivalents at the beginning of Period   | -                    | -                    |
|  | (1,808,234)          | (3,533,165           |
|  | 8,644,771            | 20,758,133           |
| Cash and cash equivalents at the end of year   | 6,836,538            | 17,224,968           |
|  |                      |                      |

#### SELECTED NOTES TO THE CONDENSED INTERIM FINANCIAL INFORMATION (UN-AUDITED) FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2023

#### 1. THE COMPANY & ITS OPERATIONS

1.1 Nazir Cotton Mills Limited is a Public Limited Company incorporated in Pakistan under the Companies Act, 1913 (Now the Companies Act, 2017) and its shares are quoted on Karachi Stock Exchange of Pakistan. The Company is engaged in manufacturing, selling, buying and dealing of Yarn of all types. The registered office of the Company is situated at 61-K, Gulberg III, Lahore. Park Lahore Cantt. The manufacturing is located at 8-KM. Faisalabad, Aslamabad, Kharianwala, Sheikhupura.

#### 1.2 Going concern assumption

The Company has incurred after tax loss for the periodended of Rs. (2.954) million(Sep 30, 2022:Rs. 5.147 million)and its accumulated losses at the end of the period stood at Rs. 399.817 million(June 2023:Rs. 396.863 million).The Company's current liabilities: acceed its current assets at reporting date by Rs. 181.039 million(June 2023: Rs. 184.885 million).Furthermore, the Company has temporarily closed down its business operations and the production remained suspended throughout the year. These condition along with others indicate the existence of material uncertainty that may cause significant/doubt about the company's ability to continue as going concern and the company may be unable to realize its assets and discharge its liabilities in the normal course of business.

However management is expecting to revive its operations and for this the company has entered into negotiation with all the lending banks during the period. Further more it is expected that there will be excess electricity and per unit rate will be equal to neighbor countries. Management is in view that the company will restart its commercial production in foreseeable future, as the government announced textile policy and there were some benefits announced for textile sector, however, management is confident that efforts will be realized and that the company will be able to continue as a going concern.

#### 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies and methods of computationadopted for the preparation of this condensed interim financial informationare the same as applied in the preparation of preceding audited annual published financial statements of the Company for the year ended June 30, 2021.

#### 2.1 Basis of preparation

#### 2.1.1 Statement of compliance

This condensed interimfinancial informationis un-audited and has been prepared in accordance with the requirements of International Accounting Standard 34 "Interim Financial Reporting" issued by the International Accounting Standards Board (IASB) as notified under the companies Act, 2017 and provisions of and directives issued under the companies Act, 2017. Where the provisions of or directives issued under the Companies Act, 2017 differ from the IAS 34 and IFRSs, the provisions of and directives issued under the companies Act, 2017 have been followed.

This condensed interim financial informationhas, however, been subjected to limitedscope review by the statutory auditors of the Company as required by the Code of Corporate Governance, and shouldbe read in conjunctionwith the company's audited annual financial Statements for the vear ended June 30. 2021.

#### 2.1.2 Critical accounting estimates & judgments

The preparation of this condensed interim financial information conformity with approved accounting standards requires the use of certain critical accounting estimates. It also require management to exercise its judgments in the process of applying the company's accounting policies. Estimates and judgmentare continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

During the preparation of this condensed interim financial information's significant judgments made by the management in applying the Company policies and the key sources of the estimation and uncertainty were the same as those that applied in the preceding audited annual published financial statements of the company for the year ended June 30, 2023

|             |                               | September 30,<br>2023 | June 30,<br>2023 |  |
|-------------|-------------------------------|-----------------------|------------------|--|
|             |                               | (Un-audited)          | (Audited)        |  |
|             |                               | Rupees                | Rupees           |  |
| 3. <u>P</u> | PROPERTY PLANT AND EQUIPMENTS |                       |                  |  |
|             | Opening Net Book Value        | 361,977,354           | 375,748,312      |  |
|             | Addition During The Year      |                       | -                |  |
|             | Deletion During the Year      |                       |                  |  |
|             |                               | <u> </u>              | -                |  |
|             | Accumulated Depreciation      | 3,084,421             | 13,770,958       |  |
|             |                               | 3,084,421             | 13,770,958       |  |
|             | Closing Net Book ValueValue   | 358,892,933           | 361,977,354      |  |
|             |                               |                       |                  |  |

|              |  |       | September 30, | June 30,    |
|--------------|--|-------|---------------|-------------|
|              |  |       | 2023          | 2023        |
|              |  |       | (Un-audited)  | (Audited)   |
| 4. <u>s</u>  | SHORT TERM FINANCING                       |       | Rupees        | Rupees      |
| 4.1          | Financing From Banking Companies - Secured |       | 84,722,211    | 84,722,211  |
| 4.2          | Sponsors Loan                              |       | 122,174,774   | 122,174,774 |
| 4.3          | Loan from related paries - Unsecured       |       | -             | -           |
|              |  |       | 206,896,985   | 206,896,985 |
| 4.1 <u>I</u> | LOAN LIABILITIES - BANKING COMPANIES       |       | 200,090,905   | 200,070,705 |
|              | Habib Bank Limited                         | 4.1.1 | 13,258,000    | 13,258,000  |
|              | Islamic Investment Bank Limited            | 4.1.2 | 71,464,211    | 71,464,211  |
|              |  |       | 84,722,211    | 84,722,211  |
|              |  |       |               |             |

- 4.1.1 The loan is secured againstequitablemortgagecharge on all the entire present and futurefixed assets, hypothecationcharge on all the present and futurecurrentassets and personal guaranteesof all the directors of the Company. This loan was earliers ettled by the State Bank of Pakistan in December 29, 2004 which had resulted in reduction of the liability Rs. 3.580 million with no furthermarkup to be provided subject to provisions that if the Company failed to repay any of the installment han the agreementwould stood cancelled and the bank would be entitled to recover the original outstanding mount without any reduction. However, the Company failed to repay the installments and the Bank filed a case for recovery of its original liability. This loan does not carry any further markup as the
- 4.1.2 The loan was repayable in sixteenquarterly installments w.e.f. April1, 1999. It carries mark-up @ 20% per annum. Accrued mark-up has been frozen and kept in a separate account. The new mark-up on diminishing principalis also being kept in same account and repayment of this mark-up would start subject to the entire repayment of the principal mount. This loan and mark-up account are secured by Personal guarantees of directors except nomineedirector and mortgage of fixed assets to the tune of Rs.20 millionThe liquidatorof IslamicInvestmentBank has been appointed. The managementis in opinionthat as the bank is a shareholder in the profit/(losses) and that the matter is pending in the Peshawar HighCourt, therefore, no markup is payable. The company has filed a suit against the bank to recover the share of losses amounting to Rs. 110.0 (M).

| 4.2 | SPONSORS LOAN                                  |  |  |  |   |             |   |             |
|-----|--|--|--|--|---|-------------|---|-------------|
|     |  |  |  |  |   |             |   |             |
|     | Sponsors Loan - Deferred                       |  |  |  |   | 121,940,774 |   | 121,940,774 |
|     |  |  |  |  |   | 121,940,774 | _ | 121,940,774 |
| 4.3 | LOAN FROM ASSOCIATED UNDER TAKING              |  |  |  |   |             |   |             |
|     | Loans from Associated Undertakings - Unsecured |  |  |  |   | -           |   | 1,500,000   |
|     |  |  |  |  |   | -           | _ | 1,500,000   |
|     |  |  |  |  | 1 |             |   |             |

#### 5. CONTINGENCIES & COMMITMENTS

Contingencies

a) IslamicInvestmentBank (in liquidation)and case has been shifted from Lahore High Court to Peshawar High Court because, the liquidatioprocess will be completed in Peshawar. This loan and mark-up account are secured by Personal guarantees of directors except nomineedirectorand mortgageof fixed assets to the tune of Rs.20.0 millionThe liquidatorof IslamicInvestmentBank has been appointed. The managements of the opinionthat as the bank is a shareholderin the profit/(losses),therefore, the companyhas filed a suitagainst bank to recover the share of losses amounting 0 Rs. 110.0 (M) and that the matter is pending in the Peshawar High Court because the provide the provide

b) Court, hence no markup is payable.
 b) WAPDA had filed a sult against the company for recovering of arrears amountingto Rs. 12.4 (M). The Lahore High Court had decided the case in favor of WAPDA. The company had deposited Rs. 12.4 (M) with WAPDA for electricitycase as per orders of the Lahore High Court and has filed an appeal for recovery of the said amount from WAPDA in the Supreme Court. The management

Commitments

a) There were no commitments outstanding as at the balance sheet date (June 30, 2023: Nil).

#### 6. TRANSACTION WITH ASSOCIATED COMPANIES

There is no transaction with associated companies during the period.

| 7 | моу    | /EMENT IN OWNERS EQUITY   | Sep 30, 2023<br>(Un-audited) | June 30, 2023<br>(Audited) |
|---|--------|---------------------------|------------------------------|----------------------------|
|   |        |                           | Rupees                       | Rupees                     |
|   | Capita | al reserve                |                              |                            |
|   | Invest | tment revaluation reserve | 434,000                      | 434,000                    |
|   | Rever  | nue reserves:             | (479,125)                    | (479,125                   |
|   | -      | General reserve           | 45,829,500                   | 45,829,50                  |
|   | -      | Surplus on Revaluation    | 306,683,595                  | 306,683,59                 |
|   | -      | Accumulated loss          | (407,067,537                 | (407,067,53                |
|   |        |                           | (54,554,442)                 | (54,554,44)                |
|   |        |                           | (54,599,567)                 | (54,599,56)                |

#### 8. FINANCIAL RISK MANAGEMENT

The companies financial isk managementobjectives and policies are consistent with those disclosed in the audited annual financial statements of the company as at and for the year ended June 30, 2023

These condensed interimfinancialinformationStatementhas been approved by the Board of Directors of the Company and authorizedfor issue on November 06, 2023

#### 9 GENERAL

Figures have been rounded off to the nearest thousand rupee.



Ph 042-35763736, 35773742 Fax 042-35763768 If undelivered, please return to NAZIR COTTON MILLS LTD. 61-K Gulberg III, Lahore